1606 Corp. applauds Adnexus Biotechnologies' AI-developed malaria drug Trapicolast; LOI terminated but deal progressing

1606 CORP.

1606 Corp. expresses strong support for strategic investment target Adnexus Biotechnologies after Trapicolast announcement.
Trapicolast targets apicoplast and vesicular trafficking in Plasmodium; developed via Sutra™ AI platform analyzing 8M+ compounds.
Adnexus and 1606 Corp. previously signed a LOI that terminated Nov 28, 2024; parties still moving forward to close transaction.
CEO Austen Lambrecht highlights AI-driven innovation for global health challenges.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.